Results 91 to 100 of about 1,973 (178)

Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label study

SAGE Open Medicine, 2018
Objectives: The recent availability of iron-based phosphate binders has raised some concerns about iron overload in patients with end-stage renal disease.
Rosamund J Wilson, Beverly Jones, Claudio Marelli   +2 more
doaj   +1 more source

A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis

, 2018
Background and Objectives: The purpose of this study was to compare the effects of phosphate binders lanthanum carbonate (LC) versus sevelamer hydrochloride (SH) in end-stage renal disease (ESRD) patients undergoing hemodialysis.Methods: Studies ...
Li, Hongyan, Lin, Zhijun, Zhou, Tianbiao, Xie, Weiji   +3 more
core   +1 more source

Effect of switching from sevelamer hydrochloride to lanthanum carbonate on metabolic acidosis in dialysis patients

, 2013
Treatments for hyperphosphatemia in dialysis patients include dietary therapy and oral administration of phosphate binders; however, it has recently been suggested that oral administration of sevelamer hydrochloride, a phosphate binder, may cause ...
Uramatsu, Tadashi, Nishino, Tomoya, Hirose, Misaki, Funakoshi, Satoshi, Kohno, Shigeru, Harada, Takashi, Minami, Kana, Arai, Hideyuki, Obata, Yoko, Yamashita, Hiroshi   +9 more
core  

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide

International Journal of Nephrology and Renovascular Disease, 2016
Valeria Cernaro, Domenico Santoro, Antonio Lacquaniti, Giuseppe Costantino, Luca Visconti, Antoine Buemi, Michele Buemi Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy Abstract: Chronic kidney disease-mineral bone ...
Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, Buemi M   +6 more
doaj  

Comparative in vitro cytogenetic analysis of calcium carbonate and sevelamer hydrochloride agents used by patients with hyperphosphatemia.

, 2019
TEZ12037Tez (Yüksek Lisans) -- Çukurova Üniversitesi, Adana, 2019.Kaynakça (s. 85-100) var.XVII, 101 s. :_res. (bzs. rnk), tablo ;_29 cm.Bu çalışma, hiperfosfatemili hastaların tedavisinde sıklıkla reçete edilen ve fosfat bağlayıcı grubunda yer alan ...
Ulaya, Goulzar
core  

Sevelamer 'carbonate': what's in a name? [PDF]

Nephrology Dialysis Transplantation, 2010
Clive, Harland, Oliver, Wrong
openaire   +2 more sources

Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease

Therapeutics and Clinical Risk Management, 2021
Agnieszka Makowka, Michal Nowicki Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Lodz, Lodz, PolandCorrespondence: Michal NowickiDepartment of Nephrology, Hypertension and Kidney Transplantation, Medical ...
Makowka A, Nowicki M
doaj  

Study on the efficacy of sevelamer carbonate versus calcium carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis at Pusat Penyelidikan Klinikal Clinical Research Centre (CRC) Hospital Serdang / Siti Rohaya Daud [PDF]

, 2014
Hyperphosphatemia (HyperPO4) and chronic kidney disease are metabolic bone disease that is common in end stage renal disease. Untreated hyperphosphatemia can lead to cardiovascular disease and calciphylaxis. It is a risk factor for cardiovascular disease
Daud, Siti Rohaya
core  

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate

Therapeutics and Clinical Risk Management, 2008
Ismail A Mohammed, Alastair J HutchisonManchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Oxford Road, Manchester, UKAbstract: Hyperphosphatemia is an inevitable consequence of end stage chronic kidney disease and is ...
Ismail A Mohammed, Alastair J Hutchison
doaj  

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease

Therapeutics and Clinical Risk Management, 2020
Valeria Cernaro, Sebastiano Calimeri, Alfredo Laudani, Domenico Santoro Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, Messina, ItalyCorrespondence: Valeria CernaroUnit of Nephrology and Dialysis,
Cernaro V, Calimeri S, Laudani A, Santoro D   +3 more
doaj